Pancreatic Cancer Research

ResearcherNational Institutes of HealthActive in the last 2 years

Raffit Hassan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4012-3633; OpenAlex author ID A5029872582; NIH RePORTER profile ID 6189074. Sources: ClinicalTrials.gov.

Their work

Papers
2
Trials
5 (principal investigator on 4)
Grants
2
Labs led
0
Collaborators
14
Papers, trials and grants by year

2003: 1 trial · 2004: none · 2005: none · 2006: none · 2007: none · 2008: none · 2009: none · 2010: none · 2011: 2 trials · 2012: 1 paper · 2013: 1 trial · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 trial, 2 grants

Papers 2

  1. Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-19-2586↗
  2. DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0031507↗

Trials 5

  1. Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma Principal investigator NCT06885697↗
  2. Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma Principal investigator NCT01950572↗
  3. SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma Principal investigator NCT01362790↗
  4. Amatuximab for High Mesothelin Cancers Principal investigator NCT01413451↗
  5. Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors Study chair NCT00066651↗

Grants 2

  1. Adoptive cell therapy for malignant mesothelioma and other mesothelin expressing ZIABC010816↗
  2. Thoracic and Gastrointestinal Malignancies Branch Clinical Core ZIDBC011540↗

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jane B Trepel · 1 shared paper, 2020 · strength 0.10
  2. Ira Pastan · 1 shared paper, 2020 · strength 0.10
  3. Christine Alewine · 1 shared paper, 2020 · strength 0.10
  4. William Douglas Figg · 1 shared paper, 2020 · strength 0.10
  5. Zishuo I. Hu · 1 shared paper, 2020 · strength 0.10
  6. Nader N Hanna · 1 shared paper, 2012 · strength 0.03
  7. Naotake Funamizu · 1 shared paper, 2012 · strength 0.03
  8. Dong Ho Lee · 1 shared paper, 2012 · strength 0.03
  9. Geng Zhang · 1 shared paper, 2012 · strength 0.03
  10. Β. Michael Ghadimi · 1 shared paper, 2012 · strength 0.03
  11. Jochen Gaedcke · 1 shared paper, 2012 · strength 0.03
  12. H. Richard Alexander · 1 shared paper, 2012 · strength 0.03
  13. Anirban Maitra · 1 shared paper, 2012 · strength 0.03
  14. S. Perwez Hussain · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.